Management of hepatitis C virus genotype 4.
Hepatitis C virus (HCV) genotype 4 is predominantly found in the Middle East and North Africa. Because most of the large randomized controlled trials of antiviral therapy for chronic hepatitis C were conducted in North America and Europe, little is known about management of patients with this particular genotype. Based on the available data, sustained virological response rates to interferon-based therapies appear to be intermediate between the relatively resistant HCV genotype 1 and the readily responsive genotypes 2 and 3. Several large prospective studies of pegylated interferon plus ribavirin combination therapy, the current gold-standard treatment, have recently been completed and will be reviewed.
Abdo
Ayman A
AA
Liver Unit, University of Calgary, Calgary, Alberta, Canada. abdoayman@hotmail.com
Lee
Samuel S
SS
D000998:Antiviral Agents / Q000627:therapeutic use*; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D006526:Hepatitis C / Q000188:drug therapy* / Q000453:epidemiology / Q000635:transmission; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use*
D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons